Idenix Pharmaceuticals Company Profile (NASDAQ:IDIX)

About Idenix Pharmaceuticals (NASDAQ:IDIX)

Idenix Pharmaceuticals logoIdenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IDIX
  • CUSIP: 45166R20
  • Web: N/A
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -28.49
  • P/E Growth: 0
Dividend:
  • Dividend Yield: 1.0%
 
Frequently Asked Questions for Idenix Pharmaceuticals (NASDAQ:IDIX)

What is Idenix Pharmaceuticals' stock symbol?

Idenix Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDIX."

Who are some of Idenix Pharmaceuticals' key competitors?

How do I buy Idenix Pharmaceuticals stock?

Shares of Idenix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Idenix Pharmaceuticals' stock price today?

One share of Idenix Pharmaceuticals stock can currently be purchased for approximately $24.50.


MarketBeat Community Rating for Idenix Pharmaceuticals (NASDAQ IDIX)
Community Ranking:  1.1 out of 5 ()
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  181
MarketBeat's community ratings are surveys of what our community members think about Idenix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Idenix Pharmaceuticals (NASDAQ:IDIX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Idenix Pharmaceuticals (NASDAQ:IDIX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Idenix Pharmaceuticals (NASDAQ:IDIX)
Earnings by Quarter for Idenix Pharmaceuticals (NASDAQ:IDIX)
Earnings History by Quarter for Idenix Pharmaceuticals (NASDAQ IDIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2014Q214($0.22)($0.43)($26.07) millionViewN/AView Earnings Details
5/1/2014Q114($0.19)($0.24)$0.22 million($3.01) millionViewN/AView Earnings Details
2/27/2014Q413($0.22)($0.21)$0.15 million$0.50 millionViewN/AView Earnings Details
2/25/2013Q412($0.17)($0.17)$0.74 million$0.33 millionViewN/AView Earnings Details
11/1/2012Q312($0.17)$0.03$2.60 million$32.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Idenix Pharmaceuticals (NASDAQ:IDIX)
Current Year EPS Consensus Estimate: $-0.93 EPS
Next Year EPS Consensus Estimate: $-0.86 EPS

Dividends

Dividend History for Idenix Pharmaceuticals (NASDAQ:IDIX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Idenix Pharmaceuticals (NASDAQ:IDIX)
Insider Trades by Quarter for Idenix Pharmaceuticals (NASDAQ:IDIX)
Insider Trades by Quarter for Idenix Pharmaceuticals (NASDAQ:IDIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/31/2014Baupost Group Llc/Mamajor shareholderBuy16,420,241$6.50$106,731,566.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Idenix Pharmaceuticals (NASDAQ:IDIX)
Latest Headlines for Idenix Pharmaceuticals (NASDAQ:IDIX)
Source:
DateHeadline
bizjournals.com logoHere's where Merck's new Cambridge research facility will be located
www.bizjournals.com - July 13 at 4:30 PM
fool.com logo3 Important Questions We Want Answered When Merck Reports Its Q2 Results
www.fool.com - July 27 at 9:02 AM
cnbc.com logoActivists want 'imminent retirement' of Ariad CEO
www.cnbc.com - February 20 at 11:24 AM
finance.yahoo.com logoMerck 2Q profit more than doubles
finance.yahoo.com - July 29 at 11:45 AM

Social

Chart

Idenix Pharmaceuticals (IDIX) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff